| scholarly article | Q13442814 |
| P356 | DOI | 10.18632/ONCOTARGET.5001 |
| P8608 | Fatcat ID | release_rnl74a3rqrctdhdgqyr4lsfqau |
| P932 | PMC publication ID | 4745734 |
| P698 | PubMed publication ID | 26336821 |
| P5875 | ResearchGate publication ID | 281514404 |
| P2093 | author name string | Jun Zhang | |
| Yujie Wang | |||
| Guangyu Liu | |||
| Yingjian Zhang | |||
| Xiao Bao | |||
| Miao Mo | |||
| Jingyi Cheng | |||
| Daoying Geng | |||
| P2860 | cites work | Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes | Q83880963 |
| Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography combined with ultrasonography-guided fine needle aspiration cytology for identifying axillary lymph node status in patients with breast cancer | Q85349967 | ||
| Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer | Q33641143 | ||
| Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients | Q33847261 | ||
| Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy | Q34051790 | ||
| Similar prognoses for invasive micropapillary breast carcinoma and pure invasive ductal carcinoma: a retrospectively matched cohort study in China | Q34133961 | ||
| Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATA | Q35471517 | ||
| American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer | Q36678853 | ||
| HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment | Q37185872 | ||
| Response to trastuzumab by HER2 expressing breast tumour xenografts is accompanied by decreased Hexokinase II, glut1 and [18F]-FDG incorporation and changes in 31P-NMR-detectable phosphomonoesters. | Q39239280 | ||
| Prognostic Impact of [18F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy | Q43272230 | ||
| Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla | Q45023166 | ||
| Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. | Q46765380 | ||
| Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer | Q49017971 | ||
| FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial results. | Q51347358 | ||
| FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer. | Q53120559 | ||
| FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients. | Q53245198 | ||
| 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO. | Q54405367 | ||
| Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. | Q54671187 | ||
| Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2–Overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial | Q57579656 | ||
| Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer | Q73675183 | ||
| Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18 | Q77438388 | ||
| Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis | Q81353372 | ||
| P433 | issue | 30 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 29388-29395 | |
| P577 | publication date | 2015-08-21 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer | |
| P478 | volume | 6 |
| Q43082312 | Complete Metabolic Response on Interim 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Long-Term Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy |
| Q47727855 | Decreased background parenchymal enhancement of the contralateral breast after two cycles of neoadjuvant chemotherapy is associated with tumor response in HER2-positive breast cancer |
| Q104064435 | Early prediction of neoadjuvant chemotherapy response for advanced breast cancer using PET/MRI image deep learning |
| Q90260579 | PET/CT-Based Response Evaluation in Cancer-a Systematic Review of Design Issues |
| Q36653693 | The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. |
| Q36364739 | The accuracy of (18)F-FDG PET/CT in predicting the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis and systematic review |
| Q55286904 | [18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer. |
| Q38693888 | ¹⁸F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials |
Search more.